237 related articles for article (PubMed ID: 25431369)
1. Prognostic significance of pre-operative C-reactive protein and the neutrophil-lymphocyte ratio in resectable pancreatic cancer: a systematic review.
Stevens L; Pathak S; Nunes QM; Pandanaboyana S; Macutkiewicz C; Smart N; Smith AM
HPB (Oxford); 2015 Apr; 17(4):285-91. PubMed ID: 25431369
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of pre-operative inflammatory markers in resected gallbladder cancer: a systematic review.
Saqib R; Pathak S; Smart N; Nunes Q; Rees J; Finch Jones M; Poston G
ANZ J Surg; 2018 Jun; 88(6):554-559. PubMed ID: 29205753
[TBL] [Abstract][Full Text] [Related]
3. A meta-analysis of the utility of the neutrophil-to-lymphocyte ratio in predicting survival after pancreatic cancer resection.
Mowbray NG; Griffith D; Hammoda M; Shingler G; Kambal A; Al-Sarireh B
HPB (Oxford); 2018 May; 20(5):379-384. PubMed ID: 29336893
[TBL] [Abstract][Full Text] [Related]
4. The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients.
Cheng H; Luo G; Lu Y; Jin K; Guo M; Xu J; Long J; Liu L; Yu X; Liu C
Pancreatology; 2016; 16(6):1080-1084. PubMed ID: 27665172
[TBL] [Abstract][Full Text] [Related]
5. Preoperative Neutrophil-Lymphocyte and Lymphocyte-Monocyte Ratios Reflect Immune Cell Population Rearrangement in Resectable Pancreatic Cancer.
Sierzega M; Lenart M; Rutkowska M; Surman M; Mytar B; Matyja A; Siedlar M; Kulig J
Ann Surg Oncol; 2017 Mar; 24(3):808-815. PubMed ID: 27770341
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: a meta-analysis.
Yang JJ; Hu ZG; Shi WX; Deng T; He SQ; Yuan SG
World J Gastroenterol; 2015 Mar; 21(9):2807-15. PubMed ID: 25759553
[TBL] [Abstract][Full Text] [Related]
7. Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
Sanjay P; de Figueiredo RS; Leaver H; Ogston S; Kulli C; Polignano FM; Tait IS
JOP; 2012 Mar; 13(2):199-204. PubMed ID: 22406601
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of neutrophil-lymphocyte ratio and level of C-reactive protein in a large cohort of pancreatic cancer patients: a retrospective study in a single institute in Japan.
Inoue D; Ozaka M; Matsuyama M; Yamada I; Takano K; Saiura A; Ishii H
Jpn J Clin Oncol; 2015 Jan; 45(1):61-6. PubMed ID: 25341546
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer.
Asaoka T; Miyamoto A; Maeda S; Tsujie M; Hama N; Yamamoto K; Miyake M; Haraguchi N; Nishikawa K; Hirao M; Ikeda M; Sekimoto M; Nakamori S
Pancreatology; 2016; 16(3):434-40. PubMed ID: 26852169
[TBL] [Abstract][Full Text] [Related]
10. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
[TBL] [Abstract][Full Text] [Related]
11. Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma.
Garcea G; Ladwa N; Neal CP; Metcalfe MS; Dennison AR; Berry DP
World J Surg; 2011 Apr; 35(4):868-72. PubMed ID: 21312035
[TBL] [Abstract][Full Text] [Related]
12. The Combination of Neutrophil-to-lymphocyte Ratio and Serum Carbohydrate Antigen 19-9 Level as a Prognostic Indicator in Patients with Recurrent Pancreatic Cancer.
Sakamoto T; Saito H; Uchinaka EI; Morimoto M; Amisaki M; Tokuyasu N; Honjo S; Ashida K; Fujiwara Y
Anticancer Res; 2018 Sep; 38(9):5497-5503. PubMed ID: 30194208
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of neutrophil-lymphocyte ratio in resectable pancreatic neuroendocrine tumors with special reference to tumor-associated macrophages.
Harimoto N; Hoshino K; Muranushi R; Hagiwara K; Yamanaka T; Ishii N; Tsukagoshi M; Igarashi T; Tanaka H; Watanabe A; Kubo N; Araki K; Hosouchi Y; Suzuki H; Arakawa K; Hirai K; Fukazawa T; Ikota H; Shirabe K
Pancreatology; 2019 Sep; 19(6):897-902. PubMed ID: 31409525
[TBL] [Abstract][Full Text] [Related]
14. Validation of the pretreatment neutrophil-lymphocyte ratio as a predictor of overall survival in a cohort of patients with pancreatic ductal adenocarcinoma.
Ben Q; An W; Wang L; Wang W; Yu L; Yuan Y
Pancreas; 2015 Apr; 44(3):471-7. PubMed ID: 25423560
[TBL] [Abstract][Full Text] [Related]
15. C-Reactive Protein-based Prognostic Measures Are Superior at Predicting Survival Compared with Peripheral Blood Cell Count-based Ones in Patients After Curative Resection for Pancreatic Cancer.
Fujiwara Y; Haruki K; Shiba H; Hamura R; Horiuchi T; Shirai Y; Furukawa K; Gocho T; Yanaga K
Anticancer Res; 2018 Nov; 38(11):6491-6499. PubMed ID: 30396977
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory response related scoring systems in assessing the prognosis of patients with pancreatic ductal adenocarcinoma: a systematic review.
Ahmad J; Grimes N; Farid S; Morris-Stiff G
Hepatobiliary Pancreat Dis Int; 2014 Oct; 13(5):474-81. PubMed ID: 25308357
[TBL] [Abstract][Full Text] [Related]
17. The novel index using preoperative C-reactive protein and neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with pancreatic cancer.
Taniai T; Haruki K; Furukawa K; Onda S; Yasuda J; Shirai Y; Gocho T; Yanagaki M; Hamura R; Shiba H; Ikegami T
Int J Clin Oncol; 2021 Oct; 26(10):1922-1928. PubMed ID: 34110531
[TBL] [Abstract][Full Text] [Related]
18. Preoperative neutrophil-to-lymphocyte ratio as a prognosticator in early stage pancreatic ductal adenocarcinoma.
Abe T; Amano H; Kobayashi T; Hanada K; Nakahara M; Ohdan H; Noriyuki T
Eur J Surg Oncol; 2018 Oct; 44(10):1573-1579. PubMed ID: 29807728
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment blood neutrophil/lymphocyte ratio is associated with metastasis and predicts survival in patients with pancreatic cancer.
Guo J; Wu M; Guo L; Zuo Q
Bull Cancer; 2018 Feb; 105(2):146-154. PubMed ID: 29290332
[TBL] [Abstract][Full Text] [Related]
20. Platelet × CRP Multiplier Value as an Indicator of Poor Prognosis in Patients With Resectable Pancreatic Cancer.
Miyamoto R; Oda T; Hashimoto S; Kurokawa T; Kohno K; Akashi Y; Ohara Y; Yamada K; Enomoto T; Ohkohchi N
Pancreas; 2017 Jan; 46(1):35-41. PubMed ID: 27984485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
